- Home
- OGI vs CRVS Comparison
OGI vs CRVS Comparison
Compare OGI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- CRVS
- Stock Information
- Founded
- OGI 2013
- CRVS 2014
- Country
- OGI Canada
- CRVS United States
- Employees
- OGI N/A
- CRVS N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- OGI Health Care
- CRVS Health Care
- Exchange
- OGI Nasdaq
- CRVS Nasdaq
- Market Cap
- OGI 176.1M
- CRVS 161.4M
- IPO Year
- OGI N/A
- CRVS 2016
- Fundamental
- Price
- OGI $1.89
- CRVS $5.78
- Analyst Decision
- OGI
- CRVS Buy
- Analyst Count
- OGI 0
- CRVS 4
- Target Price
- OGI N/A
- CRVS $10.83
- AVG Volume (30 Days)
- OGI 424.2K
- CRVS 468.1K
- Earning Date
- OGI 08-13-2024
- CRVS 11-05-2024
- Dividend Yield
- OGI N/A
- CRVS N/A
- EPS Growth
- OGI N/A
- CRVS N/A
- EPS
- OGI N/A
- CRVS N/A
- Revenue
- OGI $110,297,722.00
- CRVS N/A
- Revenue This Year
- OGI $8.76
- CRVS N/A
- Revenue Next Year
- OGI $14.04
- CRVS N/A
- P/E Ratio
- OGI N/A
- CRVS N/A
- Revenue Growth
- OGI 2.33
- CRVS N/A
- 52 Week Low
- OGI $0.97
- CRVS $1.05
- 52 Week High
- OGI $2.91
- CRVS $6.15
- Technical
- Relative Strength Index (RSI)
- OGI 55.81
- CRVS 79.19
- Support Level
- OGI $1.76
- CRVS $3.90
- Resistance Level
- OGI $1.89
- CRVS $4.75
- Average True Range (ATR)
- OGI 0.09
- CRVS 0.40
- MACD
- OGI -0.01
- CRVS 0.09
- Stochastic Oscillator
- OGI 77.27
- CRVS 83.56
About OGI Organigram Holdings Inc.
OrganiGram Holdings Inc is engaged in producing indoor-grown cannabis for patients and adult recreational consumers in Canada. The company has also developed a portfolio of adult-use recreational cannabis brands including Edison, Big Bag o' Buds, SHRED, Monjour, Holy Mountain, and Trailblazer. Tremblant Cannabis, and artisanal craft brand, Laurentian are recent additions to Organigram's existing brand portfolio.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).